|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 269.35 DKK | +2.49% |
|
+14.69% | -42.24% |
| 12/03 | Deutsche Bank cuts Zealand Pharma price target to DKK 275 (450), reiterates Hold | FW |
| 12/03 | Zealand Pharma A/S Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 02:00 PM |
| Capitalization | 1.86TCr 286.09Cr 248.18Cr 224.4Cr 214.26Cr 389.72Cr 26TCr 403.36Cr 2.67TCr 1.06TCr 13TCr 1.07TCr 1.05TCr 46TCr | P/E ratio 2026 * |
14x | P/E ratio 2027 * | -573x |
|---|---|---|---|---|---|
| Enterprise value | 669.32Cr 103.2Cr 90Cr 81Cr 77Cr 140.58Cr 9.53TCr 145.5Cr 963.32Cr 382.51Cr 4.55TCr 387.26Cr 379Cr 16TCr | EV / Sales 2026 * |
1.54x | EV / Sales 2027 * | 1.78x |
| Free-Float |
99.18% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | +2.47% | ||
| 1 week | +14.69% | ||
| Current month | -25.95% | ||
| 1 month | -32.60% | ||
| 3 months | -44.60% | ||
| 6 months | -37.16% | ||
| Current year | -42.24% |
| 1 week | 233.5 |  | 272.3 |
| 1 month | 233.5 | | 407 |
| Current year | 233.5 | | 478.5 |
| 1 year | 233.5 | | 620 |
| 3 years | 205.6 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 30/03/2022 | |
| Director of Finance/CFO | - | 01/11/2022 | |
David Kendall
CTO | Chief Tech/Sci/R&D Officer | 64 | 02/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 19/04/2018 |
| Director/Board Member | 67 | 04/04/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.49% | +14.69% | -55.25% | +20.27% | 286.09Cr | |
| -0.42% | -1.48% | +14.62% | +87.98% | 4.35TCr | |
| -1.06% | -0.58% | +49.23% | +14.57% | 3.99TCr | |
| -0.10% | -0.74% | +85.29% | +659.28% | 3.01TCr | |
| -0.11% | -10.71% | -7.01% | -30.16% | 2.16TCr | |
| -1.71% | -2.60% | +46.27% | -33.62% | 1.86TCr | |
| -1.34% | -0.38% | +25.97% | -30.93% | 1.65TCr | |
| -0.81% | +8.04% | +53.91% | +180.41% | 1.31TCr | |
| +6.95% | +9.43% | -13.84% | +980.72% | 1.2TCr | |
| +1.75% | +6.76% | +68.43% | - | 1.16TCr | |
| Average | +0.55% | -3.19% | +26.76% | +205.39% | 2.1TCr | |
| Weighted average by Cap. | -0.12% | -1.82% | +35.65% | +184.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 434.35Cr 67Cr 58Cr 53Cr 50Cr 91Cr 6.18TCr 94Cr 625.13Cr 248.22Cr 2.95TCr 251.3Cr 245.95Cr 11TCr | 390.18Cr 60Cr 52Cr 47Cr 45Cr 82Cr 5.55TCr 85Cr 561.57Cr 222.98Cr 2.65TCr 225.75Cr 220.94Cr 9.58TCr |
| Net income | 133.98Cr 21Cr 18Cr 16Cr 15Cr 28Cr 1.91TCr 29Cr 192.83Cr 77Cr 911.27Cr 78Cr 76Cr 3.29TCr | -3.53Cr -54.36L -47.16L -42.64L -40.71L -74.05L -50Cr -76.64L -5.07Cr -2.01Cr -24Cr -2.04Cr -2Cr -87Cr |
| Net Debt | -1.19TCr -182.89Cr -158.66Cr -143.46Cr -136.97Cr -249.14Cr -17TCr -257.86Cr -1.71TCr -677.92Cr -8.07TCr -686.33Cr -671.7Cr -29TCr | -1.16TCr -178.81Cr -155.12Cr -140.25Cr -133.92Cr -243.58Cr -17TCr -252.11Cr -1.67TCr -662.78Cr -7.89TCr -671.01Cr -656.7Cr -28TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 268.90 kr | +2.32% | 2,48,474 |
| 12/26/12 | 262.80 kr | -2.67% | 4,14,558 |
| 11/26/11 | 270.00 kr | +3.97% | 5,49,026 |
| 10/26/10 | 259.70 kr | +1.52% | 5,62,230 |
| 09/26/09 | 255.80 kr | +8.90% | 12,14,524 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition